- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04340258
Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC
March 28, 2024 updated by: Chad Zender, University of Cincinnati
Phase 1b/II Trial Combining PD1 Inhibition (Pembrolizumab) and Cesium 131 Brachytherapy With Salvage Surgery to Enhance Immunogenicity and Improve Local Control in Head and Neck Cancer
To Study Perioperative PD-1 Inhibitor and Cesium-131 Interstitial Brachytherapy in patients with locally recurrent HNSCC eligible for salvage surgery.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is a non-randomized, single-arm, multi-institutional phase 1b/II study including patients with locally recurrent head and neck cancer eligible for resection.
Patients who are identified to be eligible for surgical resection will be screened and consented to receive one 200mg IV dose of pembrolizumab followed by salvage surgery.
At the time of surgery, they will have Cesium131 seeds implanted.
Two to six weeks after surgery, subjects will be started on 200 mg IV of pembrolizumab to be continued every 3 weeks for 6 months.
The phase 1b part will enroll 3 patients for a safety run-in, followed by the phase 2 part if no DLTs are seen in these 3 patients.
Phase 2 will be used to estimate the 2-year DFS in comparison to a benchmark selected based on a historical control.
For correlative studies, archived tissue and surgical specimen will be evaluated by H&E and IHC for immune phenotype.
Blood samples will also be collected as shown in schema above for correlative studies (blood will be collected for correlatives and biomarkers before and after the first of pembrolizumab, before starting adjuvant pembrolizumab and at completion of 6 month course of adjuvant pembrolizumab).
Patients will be followed approximately every 3 weeks during treatment for the first 6 months, then monthly for 3 months following treatment and then every 3 months thereafter for 24 months for disease free survival (DFS) and overall survival (OS).
Study Type
Interventional
Enrollment (Estimated)
50
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: UCCC Clinical Trials Office
- Phone Number: 513-584-7698
- Email: cancer@uchealth.com
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- University of Cincinnati Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19144
- Thomas Jefferson
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- locally recurrent HNSCC and be eligible for salvage surgery
- If patient received radiation therapy in the past, they should have recovered from the acute toxicity to <grade 1
- tumor needs to be deemed resectable
Exclusion Criteria:
- Exposed carotid artery preoperatively requiring sacrifice or bypass intra-operatively
- Patients with active pharyngo-cutaneous
- Patients with more than one site of distant metastatic disease
- Prior immune-based anticancer therapy within last six months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pembrolizumab & Cesium-131
200 mg Pembrolizumab (Day -14 pre-surgery; Every 3 weeks after surgery) + Cesium-131 Seeds to deliver 60-70Gy of radiation (Single dose at the time of salvage surgery)
|
Cs-131 brachytherapy seed is a low-energy-gamma isotope that is contained in a titanium capsule.
Dosing will be determined by a radiation oncologist study team member based on CT scan and intraoperative findings.
The number of seeds and spacing will be outlined preoperatively based on the proposed square area of exposure in the resection bed.
The plan is to deliver a total of 60-70Gy of radiation to the site.
Other Names:
Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks.
The drug will be infused through a peripheral line or an indwelling catheter.
The first dose will be given 2 weeks prior to surgery.
Post-surgery, pembrolizumab will be started between 2 and 6 weeks and will continue every 3 weeks for a duration of 6 months.
Study Drug may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.
The Investigator's Brochure contains specific instructions for the preparation of the standard of care pembrolizumab infusion fluid.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Safety measured by dose limiting toxicities (DLTs).
Time Frame: 2 years
|
Phase Ib: To determine the safety of the combination of pembrolizumab and Cesium-131 in recurrent HNSCC patients undergoing salvage surgical resection.
A 3+3 safety run in will be conducted for the phase 1b part of the protocol.
Safety monitoring will begin at the time of enrollment on the study and will continue for at least 4 weeks after completion of the last treatment dose on study.
|
2 years
|
Disease-free survival
Time Frame: 2 years
|
Phase II: To estimate the disease-free survival (DFS) rate for the combination of pembrolizumab and Cesium 131 in recurrent HNSCC patients undergoing salvage surgical resection
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: 4 years
|
To estimate the Overall Survival (OS) Rate
|
4 years
|
Loco-regional control rate
Time Frame: 4 years
|
To estimate the Loco-regional control rate (LCR)
|
4 years
|
Adverse events
Time Frame: 4 years
|
To estimate the frequency and severity of adverse events (AE)
|
4 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Chad Zender, MD, University of Cincinnati
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 4, 2021
Primary Completion (Estimated)
February 4, 2025
Study Completion (Estimated)
February 4, 2025
Study Registration Dates
First Submitted
April 5, 2020
First Submitted That Met QC Criteria
April 7, 2020
First Posted (Actual)
April 9, 2020
Study Record Updates
Last Update Posted (Actual)
March 29, 2024
Last Update Submitted That Met QC Criteria
March 28, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Head and Neck Neoplasms
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Pembrolizumab
Other Study ID Numbers
- UCCC-HN-20-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HNSCC
-
Groupe Oncologie Radiotherapie Tete et CouCompleted
-
Groupe Oncologie Radiotherapie Tete et CouUNICANCER; Center Eugene MarquisActive, not recruiting
-
Groupe Oncologie Radiotherapie Tete et CouUNICANCERActive, not recruiting
-
The Netherlands Cancer InstituteCompleted
-
SparX Biotech(Jiangsu) Co., Ltd.RecruitingSolid Tumor | CRC | HNSCC | RCCUnited States
-
MediLink Therapeutics (Suzhou) Co., Ltd.RecruitingBreast Cancer | NSCLC | HNSCC | Locally Advanced or Metastatic Solid TumorsChina
-
Sichuan Cancer Hospital and Research InstituteRecruiting
-
National Cancer Institute (NCI)RecruitingGastroesophageal Junction (GEJ) Cancers | Advanced HNSCCUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityCompletedMRI | HNSCC | AI | RadiomicChina
-
CJ Bioscience, Inc.RecruitingMelanoma | NSCLC | Metastatic Cancer | Advanced Solid Tumor | Advanced Cancer | HNSCCKorea, Republic of
Clinical Trials on Cesium-131
-
Case Comprehensive Cancer CenterCompletedHead and Neck Cancer | Head and Neck Squamous Cell CarcinomaUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedRecurrent Head and Neck CarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterGT Medical Technologies, Inc.RecruitingRecurrent Brain MetastasesUnited States
-
Ronald M. Benoit, MDWithdrawnProstate CancerUnited States
-
IsoRay Medical, Inc.WithdrawnNSCLC | Non Small Cell Lung CancerUnited States
-
Cellectar Biosciences, Inc.Active, not recruitingOsteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | Pediatric Brain Tumor | DIPG | Pediatric Solid Tumor | Pediatric LymphomaUnited States, Australia, Canada
-
Cellectar Biosciences, Inc.National Cancer Institute (NCI)RecruitingHigh-Grade GliomaUnited States, Canada
-
Stealth BioTherapeutics Inc.ICON Clinical ResearchCompletedReperfusion Injury | STEMIUnited States, Hungary, Germany, Poland
-
University of Wisconsin, MadisonNational Institute of Dental and Craniofacial Research (NIDCR); Cellectar Biosciences...Active, not recruiting
-
Cellectar Biosciences, Inc.RecruitingMultiple Myeloma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Central Nervous System LymphomaUnited States, Australia, Czechia, Greece, Israel, Brazil, Finland, France, Spain, Turkey, United Kingdom